Sucampo Pharma (SCMP) Tops Q3 EPS by 2c, Guidance Beats
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Sucampo Pharma (NASDAQ: SCMP) reported Q3 EPS of $0.28, $0.02 better than the analyst estimate of $0.26. Revenue for the quarter came in at $57.9 million versus the consensus estimate of $51.46 million.
Sucampo Pharma sees FY2016 EPS of $1.20-$1.25, versus the consensus of $1.04. Sucampo Pharma sees FY2016 revenue of $220-225 million, versus the consensus of $205.7 million.
For earnings history and earnings-related data on Sucampo Pharma (SCMP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vera Bradley (VRA) Tops Q3 EPS by 1c; Offers Light Q4 Outlook; Enters New Licensing Agreements
- Hooker Furniture (HOFT) Tops Q3 EPS by 10c
- Bob Evans Farms (BOBE) Tops Q2 EPS by 11c; FY17 adj.-EPS Outlook Boosted
Create E-mail Alert Related CategoriesEarnings, Guidance
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!